MedTrace Logo

Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone

NCT05845125 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-25

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of mild hydraulic distension with intra-articular corticosteroid injection for the treatment of subacute hemiparetic shoulder pain with a capsular pattern of restricted shoulder motion.

Conditions

  • Shoulder Pain

Interventions

OTHER

Physiotherapy alone

Physiotherapy focusing on increasing the shoulder range of motion.

DRUG

Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy

The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5" spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint.

Sponsors & Collaborators

  • Fédération des médecins résidents du Québec

    collaborator UNKNOWN

  • Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal

    collaborator OTHER

  • Claire Bourgeois

    lead OTHER_GOV

Principal Investigators

  • Claire Bourgeois, BSc MD · Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal : IRGLM

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-21
Primary Completion
2024-05-21
Completion
2024-05-21

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05845125 on ClinicalTrials.gov